Cindy R. Tahl
Net Worth

Last updated:

What is Cindy R. Tahl net worth?

The estimated net worth of Ms. Cindy R. Tahl is at least $37,091,224 as of 9 Jan 2024. She owns shares worth $162,263 as insider, has earned $32,248,961 from insider trading and has received compensation worth at least $4,680,000 in Fate Therapeutics, Inc..

What is the salary of Cindy R. Tahl?

Ms. Cindy R. Tahl salary is $585,000 per year as Gen. Counsel & Corporation Sec. in Fate Therapeutics, Inc..

How old is Cindy R. Tahl?

Ms. Cindy R. Tahl is 52 years old, born in 1973.

What stocks does Cindy R. Tahl currently own?

As insider, Ms. Cindy R. Tahl owns shares in one company:

Company Title Shares Price per share Total value
Fate Therapeutics, Inc. (FATE) Gen. Counsel & Corporation Sec. 142,361 $1.14 $162,263

What does Fate Therapeutics, Inc. do?

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE logo
FATE
Fate Therapeutics, Inc.
$1.14

Cindy R. Tahl insider trading

Fate Therapeutics, Inc.

Ms. Cindy R. Tahl has made 30 insider trades between 2017-2024, according to the Form 4 filled with the SEC. Most recently she sold 10,874 units of FATE stock worth $47,519 on 9 Jan 2024.

The largest trade she's ever made was exercising 55,534 units of FATE stock on 1 Jul 2021. As of 9 Jan 2024 she still owns at least 142,361 units of FATE stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 10,874 $4.37 $47,519
Sale
Common Stock 24,363 $2.4 $58,471
Sale
Common Stock 11,553 $5.24 $60,538
Sale
Common Stock 25,000 $22.96 $574,000
Option
Common Stock 25,000 $6.55 $163,750
Option
Stock Option (Right to Buy) 25,000 $6.55 $163,750
Option
Stock Option (Right to Buy) 19,433 $4.84 $94,056
Option
Stock Option (Right to Buy) 5,567 $6.55 $36,464
Option
Common Stock 5,567 $6.55 $36,464
Sale
Common Stock 25,000 $38.85 $971,250
Option
Common Stock 19,433 $4.84 $94,056
Sale
Common Stock 5,419 $48.81 $264,474
Sale
Common Stock 7,738 $46.76 $361,829
Sale
Common Stock 50,000 $59.19 $2,959,600
Option
Stock Option (Right to Buy) 50,000 $6.55 $327,500
Option
Common Stock 50,000 $6.55 $327,500
Option
Stock Option (Right to Buy) 50,000 $6.55 $327,500
Option
Common Stock 50,000 $6.55 $327,500
Sale
Common Stock 50,000 $58.89 $2,944,600
Option
Common Stock 55,534 N/A N/A
Sale
Common Stock 55,534 $91.32 $5,071,198
Option
Stock Option (Right to Buy) 55,534 N/A N/A
Sale
Common Stock 55,534 N/A N/A
Option
Stock Option (Right to Buy) 28,149 N/A N/A
Option
Stock Option Right to Buy 1,851 N/A N/A
Option
Common Stock 30,000 $5.39 $161,550
Option
Common Stock 30,000 $5.39 $161,550
Sale
Common Stock 30,000 $41.56 $1,246,650
Sale
Common Stock 30,000 $84.09 $2,522,760
Sale
Common Stock 30,000 $84.09 $2,522,760
Sale
Common Stock 30,000 N/A N/A
Option
Common stock 35,000 $2.9 $101,500
Option
Stock Option (right to buy) 35,000 $2.9 $101,500
Sale
Common stock 35,000 $115.56 $4,044,635
Sale
Common stock 35,000 $115.56 $4,044,635
Sale
Common stock 3,254 $110.68 $360,140
Sale
Common stock 6,229 $114.79 $715,033
Sale
Common stock 19,282 $50.85 $980,509
Option
Common stock 19,282 $2.82 $54,279
Option
Stock Option (right to buy) 19,282 $2.82 $54,279
Option
Common stock 51,519 $2.73 $140,647
Sale
Common stock 51,519 $2.73 $140,647
Option
Stock Option (right to buy) 51,519 $2.73 $140,647
Option
Common stock 29,199 $2.73 $79,713
Sale
Common stock 29,199 $2.73 $79,713
Option
Stock Option (right to buy) 29,199 $2.73 $79,713
Sale
Common stock 35,000 $41.1 $1,438,500
Option
Common stock 35,000 $2.73 $95,550
Option
Stock Option (right to buy) 35,000 $2.73 $95,550
Sale
Common Stock 5,700 $20.72 $118,087
Sale
Common Stock 10,200 $14.24 $145,289
Option
Stock Option (right to buy) 25,000 $2.9 $72,500
Option
Common Stock 25,000 $2.9 $72,500
Sale
Common Stock 25,000 $2.9 $72,500
Sale
Common Stock 25,000 $2.9 $72,500
Option
Stock Option (right to buy) 25,000 $2.9 $72,500
Option
Common Stock 25,000 $2.9 $72,500
Option
Common Stock 25,000 $1.91 $47,800
Sale
Common Stock 25,000 $16 $400,000
Option
Stock Option (right to buy) 14,459 $2.14 $30,870
Sale
Common Stock 500 $4.1 $2,050
Sale
Common Stock 7,591 $3.83 $29,074

Fate Therapeutics key executives

Fate Therapeutics, Inc. executives and other stock owners filed with the SEC: